Spyre Therapeutics presents clinical data on three ulcerative colitis antibodies at UEGW 2026
SYRE•Spyre Therapeutics will present clinical data on SPY001, SPY002 and SPY003 at UEGW in Barcelona on Oct. 18, 2026. The antibodies have demonstrated clinical proof of concept, and combination results from the Phase 2 SKYLINE trial are expected in 2027.
1. Clinical data presentation
Spyre Therapeutics will present clinical data for SPY001, SPY002 and SPY003 at UEGW in Barcelona on Oct. 18, 2026. The antibodies have demonstrated clinical proof of concept for moderately to severely active ulcerative colitis.
2. Combination research
Preclinical results scheduled for Oct. 19 show antibody combinations improved efficacy in mice with colitis compared with individual treatments. The ongoing Phase 2 SKYLINE trial is testing the antibodies individually and in pairs, with combination results expected in 2027.
